netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Baricitinib found 15 matches
Open monograph to display formulary status BNF Category
  Baricitinib  (Olumiant®) Musculoskeletal and joint diseases - Drugs which suppress the rheumatic disease process - 10.01.03
  Baricitinib  (Olumiant®) Skin - Drugs affecting the immune response - 13.05.03
 
Non Formulary BNF Category
  Baricitinib Musculoskeletal and joint diseases - Drugs which suppress the rheumatic disease process - 10.01.03
  Baricitinib  (Olumiant®) Skin - Drugs affecting the immune response - 13.05.03


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section  NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis (13.05.03)
link in drug section Clinical Commissioning Policy Baricitinib for use in monogenic interferonopathies (adults and children 2 years and over) (210506P) (10.01.03)
link in drug section Clinical Commissioning Policy: Baricitinib for patients hospitalised due to COVID-19 (adults and children aged 2 years and over) (10.01.03)
link in drug section MHRA Drug Safety Update (Aug 2020): Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors (10.01.03)
link in drug section MHRA Drug Safety Update (Aug 2020): Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors (13.05.03)
link in drug section MHRA Drug Safety Update (Mar 2020): Baricitinib (Olumiant▼): risk of venous thromboembolism (10.01.03)
link in drug section MHRA Drug Safety Update (Mar 2020): Baricitinib (Olumiant▼): risk of venous thromboembolism (13.05.03)
link in drug section NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis (10.01.03)
link in drug section NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis (10.01.03)
link in drug section NICE TA926: Baricitinib for treating severe alopecia areata (13.05.03)
link in drug section NICE TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (10.01.03)


 
netFormulary